Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Paradigm Biopharmaceuticals Ltd (PAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9379
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma offers drugs in the injectable and tablet forms for bone marrow edema, respiratory disease, alphaviral arthritis, orthopaedic, alphavirus, and respiratory diseases. The company’s other indications include treating the allergic inflammatory response in allergic rhinitis (AR). It also conducts a phase 2b clinical trial to investigate PPS in subjects with Bone Marrow Lesions (BMLs) and osteoarthritis (OA). Paradigm Biopharma is headquartered in Melbourne, Victoria, Australia.

Paradigm Biopharmaceuticals Ltd (PAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Paradigm Biopharma Enters into Licensing Agreement with Griffith University 10
Equity Offering 11
Paradigm Biopharma Raises USD4.8 Million in Private Placement of Shares 11
Paradigm Biopharma to Raise USD0.8 Million in Share Purchase Plan 13
Paradigm BioPharma Raises USD7 Million in IPO of Shares 14
Acquisition 15
Xosoma Acquires C4M Pharma 15
Paradigm BioPharma Acquires Xosoma 16
Paradigm Biopharmaceuticals Ltd – Key Competitors 17
Paradigm Biopharmaceuticals Ltd – Key Employees 18
Paradigm Biopharmaceuticals Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Jul 28, 2017: Paradigm Biopharmaceuticals: June Quarter Update 20
Other Significant Developments 22
Oct 31, 2018: Paradigm Biopharmaceuticals: September 2018 quarterly report 22
Jul 27, 2018: Paradigm Biopharmaceuticals: June 2018 quarterly report 24
Apr 30, 2018: Paradigm: March 2018 Quarterly Report 26
Oct 31, 2017: Paradigm Biopharmaceuticals: September 2017 Quarter Update 29
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Paradigm Biopharma Enters into Licensing Agreement with Griffith University 10
Paradigm Biopharma Raises USD4.8 Million in Private Placement of Shares 11
Paradigm Biopharma to Raise USD0.8 Million in Share Purchase Plan 13
Paradigm BioPharma Raises USD7 Million in IPO of Shares 14
Xosoma Acquires C4M Pharma 15
Paradigm BioPharma Acquires Xosoma 16
Paradigm Biopharmaceuticals Ltd, Key Competitors 17
Paradigm Biopharmaceuticals Ltd, Key Employees 18
Paradigm Biopharmaceuticals Ltd, Subsidiaries 19

List of Figures
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Paradigm Biopharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Valeritas Inc:医療機器:M&Aディール及び事業提携情報
    Summary Valeritas Inc (Valeritas) is a medical technology company that develops and commercializes treatment solutions for diabetes. The company’s product includes V-Go insulin delivery device a wearable basal-bolus insulin delivery solution for patients with Type 2 diabetes. It also provides V-Go l …
  • Tokyo Gas Co Ltd (9531):電力:M&Aディール及び事業提携情報
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • Electronic Arts Inc. (EA):企業の財務・戦略的SWOT分析
    Electronic Arts Inc. (EA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kohler Co:企業の戦略的SWOT分析
    Kohler Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Amdocs Limited:企業の戦略・SWOT・財務情報
    Amdocs Limited - Strategy, SWOT and Corporate Finance Report Summary Amdocs Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Clearside BioMedical Inc (CLSD):企業の財務・戦略的SWOT分析
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • SMS Pharmaceuticals Ltd (SMSPHARMA):企業の財務・戦略的SWOT分析
    SMS Pharmaceuticals Ltd (SMSPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Itamar Medical Ltd (ITMR):企業の財務・戦略的SWOT分析
    Summary Itamar Medical Ltd (Itamar Medical) is a medical device company that develops, manufactures, and markets non-invasive medical devices for the diagnosis of cardiology disease and sleep related breathing disorders. The company develops products using its proprietary peripheral arterial tonomet …
  • Wynn Macau Ltd:企業の戦略・SWOT・財務分析
    Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report Summary Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Hoag Hospital Foundation:企業の戦略的SWOT分析
    Hoag Hospital Foundation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Sun Hung Kai Properties Limited:戦略・SWOT・企業財務分析
    Sun Hung Kai Properties Limited - Strategy, SWOT and Corporate Finance Report Summary Sun Hung Kai Properties Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Spectris plc:企業の戦略・SWOT・財務分析
    Spectris plc - Strategy, SWOT and Corporate Finance Report Summary Spectris plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Western Area Power Administration:企業の戦略的SWOT分析
    Western Area Power Administration - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Tongaat Hulett Ltd (TON):企業の財務・戦略的SWOT分析
    Tongaat Hulett Ltd (TON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Vitrolife AB (VITR):企業の財務・戦略的SWOT分析
    Summary Vitrolife AB (Vitrolife) is a developer, producer and marketer of laboratory products. The company provides products such as Oocyte retrieval needles, sperm processing, culture media, culture oil, additional culture media, micromanipulation solutions, vitrolife labware, micromanipulation pip …
  • Altium Ltd:企業の戦略・SWOT・財務情報
    Altium Ltd - Strategy, SWOT and Corporate Finance Report Summary Altium Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Anteo Diagnostics Ltd (ADO):医療機器:M&Aディール及び事業提携情報
    Summary Anteo Diagnostics Ltd (Anteo Diagnostics) is a leading medical technology company that develops and commercializes healthcare products. The company along with its subsidiaries provides immunoassays, in-vitro diagnostics, and point of care (PoC) tests to life sciences, bio-separation, clinica …
  • Maruzen Petrochemical Co Ltd:企業の戦略的SWOT分析
    Maruzen Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Anadolu Anonim Turk Sigorta Sirketi:企業の戦略・SWOT・財務情報
    Anadolu Anonim Turk Sigorta Sirketi - Strategy, SWOT and Corporate Finance Report Summary Anadolu Anonim Turk Sigorta Sirketi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆